Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our top-notch dedicated system is used to design specialised libraries for ion channels.
Fig. 1. The sreening workflow of Receptor.AI
It features detailed molecular simulations of the ion channel in its native membrane environment across its open, closed, and inactivated forms, coupled with ensemble virtual screening considering conformational mobility in these states. Potential binding sites are explored within the pore, in the gating region, and at allosteric locations to encompass all potential mechanisms of action.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
O00305
UPID:
CACB4_HUMAN
Alternative names:
Calcium channel voltage-dependent subunit beta 4
Alternative UPACC:
O00305; A7BJ74; A8K1Y4; B4DG40; O60515; Q6B000; Q96L40
Background:
The Voltage-dependent L-type calcium channel subunit beta-4, also known as Calcium channel voltage-dependent subunit beta 4, plays a crucial role in the function of calcium channels. It enhances peak calcium current, modulates voltage dependencies, and influences G protein inhibition and membrane targeting of the alpha-1 subunit.
Therapeutic significance:
Linked to diseases such as Epilepsy, idiopathic generalized 9, Juvenile myoclonic epilepsy 6, and Episodic ataxia 5, this protein's variants affect disease susceptibility. Understanding its role could lead to novel therapeutic strategies for these neurological disorders.